Bexarotene in Patients with Peripheral T-cell Lymphomas: Results of a Retrospective Study
ConclusionBexarotene monotherapy is well-tolerated and has encouraging activity in PTCL that warrants further investigation. This agent should be considered for further prospective trials in this setting.
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research
More News: Cutaneous T cell lymphoma | Hypothyroidism | Leukemia | Lymphoma | Myeloma | Study | T-cell Lymphoma | Toxicology